Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-TEA + Trastuzumab in Refractory HER2+ Metastatic Breast Cancer
NCT04120246Phase 1Suspended
- Sponsor
- Veana Therapeutics
- Start
- Apr 2020
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpha-tocopheryloxyacetic acid in HER2-positive breast cancer, sponsored by Veana Therapeutics. Primary endpoints: Incidence of adverse events up to 4 years and Clinical response rate up to 4 years. Started Apr 2020; status: suspended.
02
Drugs
alpha-tocopheryloxyacetic acid
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04120246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120246.